Waystar: Silently Taking Over Healthcare Billing

Impact · against what's priced in

Waystar appears fundamentally undervalued as strong 22% revenue growth and 40% margins contrast with a price depressed by technical private equity selling. The combination of a $200M buyback to neutralize this overhang and AI-driven product expansion provides a catalyst for price correction.

WAY+0.70

No priced-in read yet

In context

The company is delivering 22% YoY revenue growth and 40%+ profit margins while implementing a $200M buyback to offset temporary private equity selling pressure.

Read from the article alone

• revenue growth
• ai
• WAY
• acquisitions
• buybacks
• healthcare billing
• price target
• private equity

Search tags